| Website | mpmcapital.com |
| Phone | 617-425-9200 |
| Employees | |
| Description | Healthcare Venture Capital |
| Total | $690M |
| $550M HealthCare Fund, 3/07 | $550M |
| MPM BioVentures V, 2/10 | $140M |
Unique to MPM is an internal team of industry experts that has been specifically assembled not only to enable MPM to assess opportunities but to participate in the value creation and value enhancing acitivites once MPM is an investor. They believe that there senior team is the broadest and deepest team in healthcare venture capital, comprised of talented individuals with impressive investing and finance pedigrees, as well as persons who possess specific functional and operating expertise. MPM executives have and will continue to take interim operating positions in portfolio companies. They can “drop in” expertises in chemistry or biology, intellectual property, licensing and business development, clinical trial design and execution, and commercial operations. Whether we are helping build a company, filling in short-term management gaps, or working alongside management to prepare for key value-creating events, they do whatever it takes to help there companies succeed.
| Company | Date | Round | Size | Participants |
| Radius Health | 2/12 | Series C | $21.4M | 7 |
| Aratana Therapeutics | 12/11 | Series B | $15M | 3 |
| Verastem | 11/11 | Series C | $20M | 4 |
| Valeritas | 9/11 | Series C | $150M | 8 |
| Radius Health | 7/11 | Series C | $66M | 7 |
| Nevro | 7/11 | Unattributed | $58M | 7 |
| Verastem | 7/11 | Series B | $32M | 6 |
| Conatus Pharmaceuticals | 4/11 | Series B | $7.5M | 1 |
| Aratana Therapeutics | 1/11 | Series A | $20M | 3 |
| Verastem | 11/10 | Series A | $16M | 4 |
| iPierian | 9/10 | Series B | $28M | 8 |
| TriVascular | 8/10 | Series C | $60M | 5 |
| NeuroTherapeutics Pharma | 5/10 | Series B | $43M | 4 |
| Theraclone Sciences | 3/10 | Unattributed | $1.5M | 6 |
| Syndax Pharmaceuticals | 3/10 | Series A | $9M | 5 |
| Rhythm Pharmaceuticals | 3/10 | Series A | $21M | 2 |
| Alnara Pharmaceuticals | 1/10 | Series B | $35M | 1 |
| EndoGastric Solutions | 1/10 | Series E | $21.5M | 6 |
| Oxagen | 11/09 | Series C | $26.7M | 9 |
| TriVascular | 11/09 | Series B | $30M | 4 |
| PrimeraDx | 10/09 | Series C | $20M | 6 |
| EndoGastric Solutions | 10/09 | Unattributed | $9.5M | 6 |
| Epizyme | 10/09 | Series B | $32M | 5 |
| PharmAthene | 7/09 | Unattributed | $19.3M | 4 |
| iPierian | 7/09 | Unattributed | $11.5M | 3 |
| EndoGastric Solutions | 6/09 | Unattributed | $3.75M | 5 |
| Xanodyne | 6/09 | Series D | $38M | 7 |
| Elixir Pharmaceuticals | 5/09 | Series D | $12M | 5 |
| Taigen | 1/09 | Series C | $37M | 5 |
| KaloBios Pharmaceuticals | 12/08 | Series D | $12M | 8 |
| Radius Health | 11/08 | Series C | $15M | 6 |
| ARYx Therapeutics | 11/08 | Unattributed | $21.6M | 3 |
| Innovative Spinal Technologies | 9/08 | Series C | $18M | 2 |
| TriVascular | 3/08 | Series A | $65M | 4 |
| TriVascular2 | 3/08 | Series A | $65M | 4 |
| Allozyne | 10/07 | Series B | $30M | 5 |
| Ceregene | 6/07 | Series C | $28M | 6 |
| Radius Health | 4/07 | Series B | $57.5M | 6 |
| NeoVista | 12/06 | Series C | $41M | 6 |
| Elixir Pharmaceuticals | 11/06 | Series C | $46M | 6 |
| Chiasma | 11/06 | Series C | $44M | 4 |
| VLST Corporation | 6/06 | Series B | $55M | 7 |
| MacroGenics | 5/06 | Series C | $45M | 11 |
| Allozyne | 12/05 | Series A | $3.5M | 4 |
| Cellerant Therapeutics | 5/05 | Series B | $16M | 4 |
| EndoGastric Solutions | 9/04 | Series B | $12M | 3 |
| EndoGastric Solutions | 6/03 | Series A | $5M | 2 |
